Derivative Instruments and Hedging Activities - Classification of Gain (Loss) of Cash Flow and Fair Value Hedging Relationships (Details) - USD ($) $ in Millions	3 Months Ended															12 Months Ended
	Dec. 31, 2019	[1]	Sep. 28, 2019	[2]	Jun. 29, 2019	[3]	Mar. 30, 2019	[3]	Dec. 31, 2018	Sep. 29, 2018	[4]	Jun. 30, 2018	[5]	Mar. 31, 2018	[6]	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	$ 1,322.8		$ 1,191.1		$ 1,149.0		$ 1,174.5		$ 1,195.2	$ 1,133.1		$ 1,186.4		$ 1,217.0		$ 4,837.4	[7]	$ 4,731.7	[7]	$ 4,946.2	[7]
Cost of sales																3,064.1		2,900.2		2,966.7
Interest expense, net																121.7		128.0		168.1
Other (income) expense, net																(66.0)		$ 6.1		$ (10.1)
Foreign currency forward contracts | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																2.5
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																(2.1)
Foreign currency forward contracts | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.1
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																(1.5)
Foreign currency forward contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																0.0
Foreign currency forward contracts | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach																0.0
Treasury locks | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Treasury locks | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Treasury locks | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																(0.1)
Treasury locks | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Interest rate swap agreements | Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Interest rate swap agreements | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																0.0
Interest rate swap agreements | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																(1.8)
Interest rate swap agreements | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into earnings																$ 0.0

[1] Includes impairment charges of $141.6 million.   First
Quarter   Second
Quarter ⁽²⁾   Third
Quarter ⁽³⁾   Fourth
Quarter Year Ended December 31, 2018               Net sales $ 1,217.0
  $ 1,186.4
  $ 1,133.1
  $ 1,195.2
Gross profit $ 492.7
  $ 471.0
  $ 424.8
  $ 443.0
Change in financial assets $ 9.6
  $ (0.6 )   $ (74.9 )   $ (122.8 ) Net income (loss) $ 80.8
  $ 36.2
  $ (67.5 )   $ 81.5
Earnings (loss) per share⁽¹⁾:               Basic $ 0.57
  $ 0.26
  $ (0.49 )   $ 0.60
Diluted $ 0.57
  $ 0.26
  $ (0.49 )   $ 0.60
Weighted average shares outstanding:               Basic 140.8
  138.1
  137.4
  135.9
Diluted 141.4
  138.7
  137.4
  136.3

[2] ludes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.(4) Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.

[3] Includes change in financial assets of $10.4 million.

[4] Includes impairment charges of $221.8 million and restructuring charges and other termination benefits of $18.0 million.

[5] Includes acquisition-related charges and contingent consideration adjustments of $53.2 million.

[6] The sum of individual per share amounts may not equal due to rounding.

[7] The net sales by geography is derived from the location of the entity that sells to a third party.